NexturnBioscience (Korea) Performance
| 089140 Stock | KRW 3,395 100.00 3.03% |
On a scale of 0 to 100, NexturnBioscience holds a performance score of 4. The company secures a Beta (Market Risk) of -1.06, which conveys a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning NexturnBioscience are expected to decrease slowly. On the other hand, during market turmoil, NexturnBioscience is expected to outperform it slightly. Please check NexturnBioscience's sortino ratio, maximum drawdown, and the relationship between the total risk alpha and treynor ratio , to make a quick decision on whether NexturnBioscience's current price movements will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in NexturnBioscience Co are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, NexturnBioscience sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -73.3 B |
NexturnBioscience |
NexturnBioscience Relative Risk vs. Return Landscape
If you would invest 306,500 in NexturnBioscience Co on August 30, 2024 and sell it today you would earn a total of 33,000 from holding NexturnBioscience Co or generate 10.77% return on investment over 90 days. NexturnBioscience Co is generating 0.4788% of daily returns and assumes 8.2628% volatility on return distribution over the 90 days horizon. Simply put, 73% of stocks are less volatile than NexturnBioscience, and 91% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
NexturnBioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NexturnBioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NexturnBioscience Co, and traders can use it to determine the average amount a NexturnBioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.058
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 089140 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.26 actual daily | 73 73% of assets are less volatile |
Expected Return
| 0.48 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average NexturnBioscience is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NexturnBioscience by adding it to a well-diversified portfolio.
NexturnBioscience Fundamentals Growth
NexturnBioscience Stock prices reflect investors' perceptions of the future prospects and financial health of NexturnBioscience, and NexturnBioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NexturnBioscience Stock performance.
| Return On Equity | 2.07 | |||
| Return On Asset | 0.0793 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 170.8 B | |||
| Shares Outstanding | 10.43 M | |||
| Price To Earning | 78.14 X | |||
| Price To Sales | 0.68 X | |||
| Revenue | 16.97 B | |||
| EBITDA | (1.61 B) | |||
| Cash And Equivalents | 20.63 B | |||
| Total Debt | 2.19 B | |||
| Book Value Per Share | 6,540 X | |||
| Cash Flow From Operations | 3.66 B | |||
| Total Asset | 138.95 B | |||
| Retained Earnings | 24.52 B | |||
| Current Asset | 32.78 B | |||
| Current Liabilities | 2.22 B | |||
About NexturnBioscience Performance
By analyzing NexturnBioscience's fundamental ratios, stakeholders can gain valuable insights into NexturnBioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NexturnBioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NexturnBioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
,Ltd. develops and produces CNC automatic lathe machines in Korea and internationally. ,Ltd. was founded in 2000 and is based in Yongin, South Korea. NEXTURNBIO is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about NexturnBioscience performance evaluation
Checking the ongoing alerts about NexturnBioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NexturnBioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NexturnBioscience had very high historical volatility over the last 90 days | |
| The company reported the revenue of 16.97 B. Net Loss for the year was (4 B) with profit before overhead, payroll, taxes, and interest of 3 B. | |
| About 24.0% of the company shares are owned by insiders or employees |
- Analyzing NexturnBioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NexturnBioscience's stock is overvalued or undervalued compared to its peers.
- Examining NexturnBioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NexturnBioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NexturnBioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NexturnBioscience's stock. These opinions can provide insight into NexturnBioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NexturnBioscience Stock analysis
When running NexturnBioscience's price analysis, check to measure NexturnBioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NexturnBioscience is operating at the current time. Most of NexturnBioscience's value examination focuses on studying past and present price action to predict the probability of NexturnBioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NexturnBioscience's price. Additionally, you may evaluate how the addition of NexturnBioscience to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |